News

Keeping you informed of our latest breakthroughs and company developments

Keeping you informed of our latest breakthroughs and company developments

Filter by topic:

Sort by:

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

11 February 2024

United Nations International Day of Women and Girls in Science

6 February 2024

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

Westminster Higher Education Forum

11 December 2023

TauRx Co-Founder Highlights University Collaboration at Westminster Forum

1 2 3 4 ... 16

Further reading

Portrait of smiling afro senior man looking at camera on the street

Education, advocacy and resources

Read about our enduring focus on education, our ongoing work with GT Diagnostic Centre, and the important role played by patient advocacy groups across the world.

Scientific publications

Explore our contributions to the scientific community. This page lists peer-reviewed articles, research papers and academic publications authored or co-authored by TauRx scientists.

Circular Ribbons with QUESTION MARK Symbols - Blue Gradient Background - 3D Rendering

Frequently Asked Questions (FAQs)

Find out more about TauRx, Alzheimer's and how our work could impact those living with the disease